6/24/2019 8:48:35 AM
AbbVie Says FDA Lifted Partial Clinical Hold Placed On CANOVA Or M13-494
6/20/2019 1:59:50 PM
AbbVie Declares Quarterly Dividend Of $1.07/share, Payable Aug. 15/ Record July 15
6/6/2019 9:19:22 AM
AbbVie Gets Canada' Positive Recommendation For VENCLEXTA -Rituximab As Treatment For Chronic Lymphocytic Leukemia
5/30/2019 8:46:10 AM
AbbVie Presents Results From Several Studies And Trials Investigating Medicines Across More Than 15 Cancers
5/30/2019 8:03:41 AM
AbbVie Says Its MAVIRET Now Listed In New Brunswick
5/17/2019 8:51:26 AM
AbbVie Provides Update On Depatuxizumab Mafodotin, An Investigational Medicine For Newly Diagnosed Glioblastoma
5/14/2019 8:41:45 AM
AbbVie Resolves U.S. HUMIRA Litigation With Boehringer Ingelheim
4/25/2019 7:43:53 AM
AbbVie Q1 Net Income $2.456 Bln Or $1.65/shr Vs. $2.783 Bln Or $1.74/shr Last Year
4/18/2019 10:06:35 AM
Health Canada Oks SKYRIZI For Treatment Of Moderate To Severe Plaque Psoriasis
4/4/2019 10:02:44 AM
AbbVie Announces New Formulary Listings For Hepatitis C Treatment MAVIRET
3/26/2019 1:03:33 AM
AbbVie Announces First Regulatory Approval Of SKYRIZI In Japan
3/22/2019 10:31:14 AM
British Columbia PharmaCare Lists AbbVie's Hepatitis C Treatment MAVIRET On Formulary